Pharmaceutical Executive September 9, 2022
Reflector

And, in equal measure, patients and doctors—as EU mulls new rules.

The announcement of a new EU plan for wider sharing of health data has won endorsement from across the health community—but this is sensitive territory, so unsurprisingly the detailed reactions vary widely, depending on whether it’s industry, patients, or healthcare professionals doing the talking.

Predictably, pharmaceutical companies in this familiar battle-ground are keen to get their hands on as much data as possible to further their own product development plans. Equally predictably, patients and doctors tend to focus on protecting privacy and ensuring data security. What is surprising this time round is that the proposal has prompted the expression of strong opinions on a previously unexplored area of health-data...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Big Data, Biotechnology, Pharma, Pharma / Biotech, Technology
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article